 
November 14, 2025 
 
Corporate Relationship Department  Manager – Listing 
M/s. BSE Ltd.     M/s. National Stock Exchange of India Ltd 
Mumbai 400 001     Mumbai 400 051 
Scrip Code: 524816    Scrip Code: NATCOPHARM 
 
Dear Sir/Madam, 
        
Sub: - Q2 FY 26 Earnings Presentation 
 
Please find enclosed herewith the Earnings Presentation for the Quarter and half year ended 
September 30, 2025. 
 
Thanking you 
 
Yours faithfully  
 
For NATCO Pharma Limited 
 
 
Ch. Venkat Ramesh  
Company Secretary & 
Compliance Officer   
 
Encl : as above 

Q2FY26
NATCO Pharma 
Limited
Earnings Presentation
Disclaimer
THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES 
(TOGETHER, THE “COMPANY”).
The material that follows is a Presentation of general background information about the Company’s activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form 
and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sol e responsibility of the Company. By accessing 
this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / 
purchase the Company shares.
This Presentation includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward- looking terminology, including the 
terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “may”, “will”, “seeks” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of 
strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation 
and include statements regarding the Company’s intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and 
the industry in which the Company operates.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not 
guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its 
competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that 
the objectives of the Company will be achieved. There are some important factors that could cause material differences to Com pany’s actual results. These include (i) our ability to successfully implement our 
strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological c hanges (v) investment and business income (vi) cash flow projections etc. (vii) exposure to 
market as well as other risks.
The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any 
information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to 
publicly amend, modify or revise any forward-looking statements based on any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained 
herein is based on management information and estimates.
Any opinions expressed in this presentation are subject to change without notice. The presentation should not be construed as legal, tax, investment or other advice. None of the Company or any of its affiliates, 
advisers or representatives accepts any liability whatsoever for any loss howsoever arising from any information presented or contained in this presentation. The information contained in this presentation has not 
been independently verified. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or 
inconsistent information or representation, if given or made, should not be relied upon as having been authorized by or on behalf of the Company. Further, past performance is not necessarily indicative of future 
results.
This document is just a Presentation for information purposes and private circulation only and is not intended to be a “prospectus” or “offer document” or a “private placement offer letter” (as defined or referred 
to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription o r sale of any securities or inviting offers from the Indian 
public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the equity shares of the Company or any 
of its subsidiaries. No part of it should form the basis of or be relied upon in connection with any investment decision or a ny contract or commitment to purchase or subscribe for any securities. None of the 
Company’s securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from.
This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This presentation is confidential and this presentation or any part thereof 
should not be used or relied upon by any other party or for any other purpose and should not be copied, reproduced, recirculated, redistributed, published in any media, website or otherwise, in any form or 
manner, in part or as a whole, without the express consent in writing of the Company. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. The distribution of this 
presentation in certain jurisdictions may be restricted by law. Accordingly, any persons in possession of the aforesaid should inform themselves about and observe any such restrictions.
NATCO Pharma Limited – Earnings Presentation Q2FY26
Total Revenue stood at INR 6,511 Mn| Pharma Export Formulations at INR 2,858 Mn | Domestic Formulations Revenue at INR 
961 
Q2FY26 - Key Business & Consolidated Financial Highlights
Total Revenue stood for Q2FY26 at INR 14,630 Mn | Pharma Export Formulations at INR 11,470 Mn | Domestic Formulations 
Revenue at 1,054 Mn 
Earnings Before Interest Tax Depreciation and Amortization stood at INR 6,792 Mn and EBITDA Margin at 46.4% for 
Q2FY26*
Profit after tax for Q2FY26 was at INR 5,179 Mn
Earnings per share for Q2FY26 was at INR 28.94 per share
*EBITDA and EBITDA Margin includes Other income; ^Payout for Adcock transaction was in Q3FY26
NATCO Pharma Limited – Earnings Presentation Q2FY26
Profit before tax for Q2FY26 was at INR 6,137 Mn
Net cash as of 30th Sept 2025 is INR 39,030 Mn^
Q2FY26 - Quarterly Performance
Revenue Breakup (%) – Q2FY26
Revenue Breakup (%) – H1FY26
Revenue Breakup  (INR Mn) Q2FY26 Q2FY25 Q1FY26
API Revenue 539 496 526
Formulation
Formulation – Exports (incl profit share, license income, 
export service income & Subsidiaries) 11,470 12,113 11,265
Formulation – Domestic 1,054 1,023 1,070
Formulations Total Revenue 12,524 13,136 12,335
Crop Health Sciences 524 141 347
Other operating & non-operating income 1,043 576 698
Consolidated Total Revenue 14,630 14,349 13,906
79.7
7.4
3.1 3.76.1
Export formulation
 Domestic Formulation
Crop Health Sciences
 API
Others
NATCO Pharma Limited – Earnings Presentation Q2FY26
78.4
7.2
3.6 3.7 7.1
Export formulation
 Domestic Formulation
Crop Health Sciences
 API
Others
Consolidated Profit & Loss Statement
*includes other income
Profit & Loss Statement (INR Mn) Q2FY26 Q2FY25 Q1FY26
Total Revenue 14,630 14,349 13,906
Total Expenses (before finance cost and depreciation) 7,838 5,668 7,579
Earnings before interest, tax, depreciation and amortization (EBITDA) 6,792 8,681 6,327
EBITDA Margin* (%) 46.4% 60.5% 45.5%
Finance cost 131 41 32
Depreciation 524 458 576
Profit before tax (PBT) 6,137 8,182 5,719
Tax 958 1,417 916
Profit after tax (PAT) 5,179 6,765 4,803
PAT Margin (%) 35.4% 47.1% 34.5%
Reported Earnings per share INR - Basic and Diluted 28.94 37.81 26.84
NATCO Pharma Limited – Earnings Presentation Q2FY26
Key Para IV products in the pipeline (Filing on NCE-1) dateKey Solo FTFs (Para IV) in the pipeline
Key Product Pipeline - USA
Brand Molecule Therapeutic segment/
Primary Indication
Kyprolis
Imbruvica
Zydelig
Lynparza
Ozempic
Balversa
Carfilzomib (10mg)
Ibrutinib (tablet) 
Idelalisib
Olaparib
Semaglutide pen 
8mg/3ml & 2 mg/3ml)
Erdafitinib
Cancer/Multiple Myeloma
Cancer/Leukaemia 
Cancer/ Blood and Bone 
Marrow Cancer
Ovarian/Breast Cancer
Diabetes
Bladder Cancer
Approved (either tentative or 
fully)
Para IVs in the pipeline, with 
over 20 FTFs (incl. Sole and 
Shared)
Wegovy
Tabrecta
Semaglutide (all 
strengths)
Capmatinib
Weight Loss
Cancer/ Lung Cancer
Brand Molecule Therapeutic segment/
Primary Indication
Eliquis
Ozempic
Pomalyst
Lonsurf
Yondelis 
Calquence
Apixaban
Semaglutide pen (2 
strengths)
Pomalidomide
Trifluridine/Tipracil
Trabectedin
Acalabrutinib
Anticogulant
Diabetes
Cancer/Multiple 
Myeloma
Metastatic colorectal 
cancer 
Advanced soft-tissue 
sarcoma/ ovarian cancer
Cancer/Blood
Kyprolis
Nurtec
Carfilzomib 60 mg/ml
Rimegepant
Cancer/Multiple 
Myeloma
Migraine
Jevtana
Everysdi
Cabazitaxel
Risdiplam Oral Solution
Cancer
Spinal Muscular Atrophy 
30 13
Data as on 30th Sept 2025
NATCO Pharma Limited – Earnings Presentation Q2FY26
Our NCE | Cell & Gene Therapy Investments
NATCO Pharma Limited – Earnings Presentation Q2FY26
eGenesis
Invested US$ 8 million in a biotechnology company 
focused on xenotransplantation, by developing safe and 
effective human compatible organs for transplant
First ever human transplant of a  genetically engineered 
pig kidney was done in March’24 
It is committed to ending the global transplant shortage 
and transforming the treatment of organ failure by 
bringing their vision closer to reality with lead programs 
in kidney, liver and heart transplantation.
NRC - 2694
NRC-2694-A is an orally administered small-molecule 
tyrosine kinase inhibitor discovered and developed by 
NATCO Pharma Limited, Hyderabad
It is being tested for the treatment of Head and Neck 
cancer). A Phase 2 clinical trial for the treatment of 
Recurrent/Metastatic Head and Neck cancer who 
progressed on Keytruda® (Pembrolizumab 
manufactured by Merck & CO) has been approved by 
US FDA
Currently, the patient recruitment is in progress, trial is 
being conducted in US and India.
Cellogen Therapeutics
Invested US$ 2 million focused on advanced cellular 
engineering methods and gene-therapy-based 
approaches 
Developing Innovative third and fourth generation CAR-T 
cell therapies for leukemia and lymphoma genetic 
therapies for beta-thalassemia and sickle cell disease
First human dosing for Leukemia will begin shortly in India
Received GMP manufacturing approvals in India.
Eyestem
Invested US$ 1 million in a cell therapy company founded 
by an experienced team of clinical research, regenerative 
medicine and ophthalmology experts, developing a 
patented experimental treatment for dry  Age-Related 
Macular Degeneration (AMD) called Eyecyte-RPE.
Phase I dosing ongoing for dry AMD in India and 
preparing for USFDA grade GMP manufacturing.
Invested US$ 1 million with focus on developing novel 
therapy for metabolic diseases
Focused on Cushing’s syndrome with expansion into 
NASH
Conducting pre-clinical animal studies.
Stero Therapeutics
1
2
3
4
5

Earnings Call Details – Q2FY26
The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice 
Chairman and Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences are as 
below:
Details of the Earnings call:
• Date: 14th November 2025
• Time: 4 PM IST
• Dial-in-Numbers: 
• India: (+91 22) 62801222 / 71158123
• US: 18667462133
• UK: 08081011573
• Singapore: 8001012045
NATCO Pharma Limited – Earnings Presentation Q2FY26
